Category Archives: Psoriasis

Finding brings scientists closer to developing treatments that target causes of painful, inflammatory skin condition

Case Western Reserve scientists have taken a huge leap toward identifying root causes of psoriasis, an inflammatory skin condition affecting 125 million people around the world. Of the roughly 50,000 proteins in the human body, researchers have zeroed in on four that appear most likely to contribute this chronic disease. The findings, published this month in Molecular & Cellular Proteomics, dramatically advance efforts to understand how psoriasis develops - and, in turn, how to stop it.

"Psoriasis affects 2 to 3 percent of the population worldwide," said senior author Nicole L. Ward, PhD, associate professor of dermatology and neurosciences, Case Western Reserve University School of Medicine. "The underlying cause of psoriasis remains unknown, and the specific signals that trigger disease onset are still being investigated. There currently is no cure."

Ward's lab is focused on studying the pathogenesis of the disease and its co-morbidities, including heart attack and stroke. Her group is actively working to identify new molecules key to the disease process that could become potential drug targets. Ward has a personal interest in this research - her father suffers from psoriasis.

Psoriasis is an autoimmune skin disease characterized by well-demarcated areas of red, raised and scaly skin next to areas of normal-appearing skin. Autoimmune diseases are those where the body launches an abnormal immune response against its own tissues. Another complication of psoriasis is joint involvement, a condition termed psoriatic arthritis.

Ward and her team first narrowed their pool of potential culprits to about 1,280 proteins that are differentially regulated in the condition. From there, they focused on five that stood out either because of their high prevalence in human psoriasis or their prominence in other studies relating to human psoriasis tissue. Ward's lab team took skin tissue samples from her well-established psoriasis transgenic mouse model, called the KC-Tie2 mouse, and compared it to skin tissue samples of normal mice. Her lab collaborated with Mark R. Chance, PhD, director of the Center for Proteomics and Bioinformatics, CWRU School of Medicine, and his team at the center to identify new proteins that were differentially regulated in the skin tissue of psoriasis mice compared to the skin tissue of healthy mice.

To ensure that the proteins identified in the mouse were important to human psoriasis, her team then examined human psoriasis skin cells, known as keratinocytes, and human psoriasis skin tissue samples to confirm the increased presence of these proteins in human disease. In the skin of the psoriasis mice, investigators first identified increases in stefin A1 (342.4-fold increased; called cystatin A in humans); slc25a5 (46.2-fold increased); serpinb3b (35.6-fold increased; called serpinB1 in humans) and KLK6 (4.7-fold increased). The team found no increases of the Rab18 protein in skin tissue of the mice, and so ruled it out as a psoriasis-generating culprit. Investigators then confirmed the increased presence of the Serpinb3b, KLK6, Stefin A1 and Slc25a5 proteins in human lesional psoriasis skin tissue, and human lesional psoriasis skin cells compared to healthy control skin tissue and skin cells.

"We were interested in looking for the increased presence of these proteins, not just in the psoriasis-like skin inflammation of the mouse, but more importantly, we needed to know how the increased presence of these proteins translated to human psoriasis," Ward said. "So we took the information we discovered in the mouse model and went back to the patients and confirmed the increase in these proteins in their lesional psoriasis skin tissue. We are really focused on, and enthusiastic about, our ability to perform successfully translational bench-to bedside-and-back-again psoriasis research here at CWRU School of Medicine Department of Dermatology and the Murdough Family Center for Psoriasis at University Hospitals Case Medical Center. It's what we excel at and what we love to do."

The next step in pursuing this line of research for Ward's team will be uncovering the role and significance of each of these proteins in the progression of psoriasis. Determining the individual contributions of each protein will help provide strategic therapeutic targets to change the course of a patient's psoriasis or, at the very least, provide a better understanding of how a change in the regulation of these proteins contributes to skin inflammation and psoriatic disease.

"We are always looking for novel targets or new insight into disease progression, remission or susceptibility," Ward said. "It's all about the patients. Even though what we are doing at the bench seems focused on mouse, the ultimate goal is to improve patient care and quality of life for patients."

The rest is here:
Case Western Reserve scientists identify proteins likely to trigger psoriasis

By RTT News, January 21, 2015, 08:42:00 PM EDT

(RTTNews.com) - Novartis AG ( NVS ) announced the US Food and Drug Administration has approved Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy, a drug that is absorbed into the bloodstream and distributed to all parts of the body, or phototherapy (light therapy).

Cosentyx is the first approved psoriasis medication to selectively bind to IL-17A and inhibit interaction with the IL-17 receptor.

The approval is based on the efficacy and safety outcomes from 10 Phase II and Phase III studies, including over 3,990 adult patients with moderate-to-severe plaque psoriasis, which demonstrated that Cosentyx resulted in clear or almost clear skin in the majority of patients and had an acceptable safety profile.

The FDA approval follows the unanimous vote by the FDA Advisory Committee in October 2014. Additionally, in January 2015, the European Commission (EC) approved Cosentyx as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.

In addition to the US, Cosentyx has been approved in the EU and Australia for the treatment of moderate-to-severe plaque psoriasis and in Japan for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA).

In addition to psoriasis, Cosentyx is also in clinical trials for the treatment of PsA and ankylosing spondylitis (AS). Global regulatory applications for secukinumab in AS and PsA are planned for 2015.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Read this article:
FDA Approves Novartis' Psoriasis Drug Cosentyx

PBR Staff Writer Published 20 January 2015

The European Commission (EC) has approved Swiss drug-maker Novartis' Cosentyx (secukinumab, formerly known as AIN457) to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.

Cosentyx 300mg is the first and only interleukin-17A (IL-17A) inhibitor to be approved in Europe providing a new first-line biologic treatment option for these patients.

At present, all biologic treatments for psoriasis, including anti-tumor necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe.

Novartis Pharmaceuticals division head David Epstein said: "With this groundbreaking news from the European Commission, clear skin may now be a reality for patients living with psoriasis.

"Nearly half of psoriasis patients are not content with current therapies, including biologic treatments, showing a significant unmet need for patients.

"Cosentyx, with a first-line systemic indication for treatment of psoriasis will provide patients a better chance of achieving clear or almost clear skin."

In Phase III clinical trials, 70% or more patients treated with Cosentyx 300mg achieved clear skin (PASI 100) or almost clear skin (PASI 90), during the first 16 weeks of treatment.

The European approval follows the recent results of the Phase IIIb CLEAR trial, which showed that Cosentyx was superior to Stelara in clearing skin of patients living with moderate-to-severe plaque psoriasis.

The company said that Cosentyx also showed superiority to Enbrel (etanercept) in clearing skin in the FIXTURE study.

View original post here:
European Commission approves Novartis' psoriasis drug Cosentyx

By RTT News, January 19, 2015, 02:05:00 AM EDT

(RTTNews.com) - Swiss drugmaker Novartis AG ( NVS ) announced that the European Commission or EC has approved Cosentyx (TM) as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.

Cosentyx is the first and only biologic that has been approved in Europe as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects. All other biologic treatments for psoriasis, including anti-tumor necrosis factor therapies and Stelara are recommended for second-line systemic therapy in Europe, according to the company.

The company said that the key treatment goal for psoriasis patients is achieving clear skin. In clinical studies, 70% or more Cosentyx 300 mg patients achieved clear skin or PASI 100 or almost clear skin or PASI 90, during the first 16 weeks of treatment and importantly, this was maintained with continued treatment in the majority of patients up to Week 52.

Novartis stated that the EU approval follows the recent results of the Phase IIIb CLEAR study, which showed that Cosentyx was superior to Stelara in clearing skin of patients living with moderate-to-severe plaque psoriasis. The CLEAR study was the second head-to-head study for Cosentyx. Cosentyx also showed superiority to Enbrel in clearing skin in the FIXTURE study.

In addition to the EU, Cosentyx has been approved in Australia for the treatment of moderate-to-severe plaque psoriasis and in Japan for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis.

Further, the company said that the US Food and Drug Administration or FDA decision in moderate-to-severe plaque psoriasis is anticipated early in 2015 following the unanimous recommendation of approval in October 2014 from the Dermatologic and Ophthalmic Drugs Advisory Committee or DODAC to the US FDA.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

More:
Novartis' Cosentyx Approved By EU For First-line Systemic Treatment Of Psoriasis

huile d #39;argan pour faire pousser vos cheveux,anti psoriasis.
http://www.facebook.com/arganabiomeryam 06.09.28.29.43 Huile anti psoriasis, anti chute, soin 25euro au lieu de 35euro. Abonnez vous c #39;est gratuit.

By: MARIMAR MERYAM

Read the rest here:
huile d'argan pour faire pousser vos cheveux,anti psoriasis. - Video

Psoriasis Cure | Skin Disorder Treatment | Homeopathy At Homeocare International
Homeocare International is best homeopathic hospital in India. Dedicated doctors and friendly staff always treat as individually. Homeocare International prefer Germany Homeopathic medicines...

By: Homeocare International Pvt Ltd

Read the original here:
Psoriasis Cure | Skin Disorder Treatment | Homeopathy At Homeocare International - Video

Solution For Psoriasis Disorder | Review for skin disorder | Homeopathy Treatment
Homeocare International is best homeopathic hospital in India. Dedicated doctors and friendly staff always treat as individually. Homeocare International prefer Germany Homeopathic medicines...

By: Homeocare International Pvt Ltd

Read more:
Solution For Psoriasis Disorder | Review for skin disorder | Homeopathy Treatment - Video

Psoriasis y Vitiligo
Ella dicide tomar StemEnhance para superar su afeccion y.... Los beneficios que obtiene nos lo cuenta en pocas palabras.

By: James Peralta

More:
Psoriasis y Vitiligo - Video

Natural Cure for Pimples, Skin Blemishes, Psoriasis, Eczema, etc
I #39;m not a skin expert but I #39;m just sharing what worked for me.

By: d17thangel

Go here to read the rest:
Natural Cure for Pimples, Skin Blemishes, Psoriasis, Eczema, etc - Video

WEDNESDAY, Jan. 7, 2015 (HealthDay News) -- Psoriasis is more than just a troublesome skin condition for millions of Americans -- it also causes up to $135 billion a year in direct and indirect costs, a new study shows.

According to data included in the study, about 3.2 percent of the U.S. population has the chronic inflammatory skin condition.

"Psoriasis patients may endure skin and joint disease, as well as associated conditions such as heart disease and depression," said Dr. Amit Garg, a dermatologist at North Shore-LIJ Health System in Manhasset, N.Y.

"These patients may bear significant long-term costs related to the medical condition itself, loss of work productivity, as well as to intangibles such as restriction in activities and poor self-image, for example," he added.

In the new study, a team led by Dr. Elizabeth Brezinski of the University of California, Davis reviewed 22 studies to estimate the total annual cost of psoriasis to Americans.

They calculated health care and other costs associated with the skin condition at between $112 billion and $135 billion in 2013.

Direct costs of psoriasis ranged from $57 billion to more than $63 billion, and indirect costs -- such as missed work days -- ranged from about $24 billion to $35 billion, the study found.

Other health problems related to psoriasis cost more than $36 billion, and treating the physical and mental health effects of psoriasis cost up to $11,498 per patient, the research team calculated.

"The direct health care costs are significantly greater for patients with psoriasis than for the general population and are also higher for patients with increasing psoriasis disease severity," the researchers concluded.

Dr. Gary Goldenberg, assistant professor of dermatology at the Icahn School of Medicine at Mount Sinai in New York City, said the findings were "not surprising."

Link:
Psoriasis Costs Americans Up to $135 Billion Annually, Study Finds